Dyne Therapeutics (DYN) News Today → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free DYN Stock Alerts $26.08 +0.08 (+0.31%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineDyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projectionsfinance.yahoo.com - May 4 at 8:34 AMHC Wainwright Reaffirms "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN)marketbeat.com - May 3 at 9:42 PMDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlightsfinanznachrichten.de - May 3 at 9:08 PMFinancial Contrast: Dyne Therapeutics (NASDAQ:DYN) versus Leap Therapeutics (NASDAQ:LPTX)americanbankingnews.com - May 3 at 1:48 AMDYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024msn.com - May 3 at 12:08 AMDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlightsfinance.yahoo.com - May 2 at 4:17 PMDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlightsglobenewswire.com - May 2 at 4:10 PMDyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Morgan Stanleyamericanbankingnews.com - May 1 at 3:50 AMMorgan Stanley Initiates Coverage of Dyne Therapeutics (DYN) with Overweight Recommendationmsn.com - April 30 at 1:26 PMDyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46marketbeat.com - April 30 at 1:06 PMDyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Morgan Stanleymarketbeat.com - April 30 at 7:22 AMVivo Capital LLC Has $46.42 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)marketbeat.com - April 27 at 9:40 PMFederated Hermes Inc. Invests $4.99 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)marketbeat.com - April 26 at 5:40 AMDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Brokeragesamericanbankingnews.com - April 24 at 2:32 AMSynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTfinanznachrichten.de - April 22 at 7:26 AMDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 18.5% in Marchmarketbeat.com - April 14 at 11:39 AMStifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)markets.businessinsider.com - April 8 at 1:46 PMDyne Therapeutics (NASDAQ:DYN) Trading Down 3%marketbeat.com - April 4 at 3:26 PMDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Assenagon Asset Management S.A.marketbeat.com - April 2 at 4:38 AMDyne Therapeutics (NASDAQ:DYN) Shares Up 9.9%marketbeat.com - March 27 at 4:44 PMDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officerglobenewswire.com - March 27 at 4:05 PMDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposiumglobenewswire.com - March 27 at 8:30 AMAnalysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)markets.businessinsider.com - March 26 at 11:06 PMOppenheimer Reiterates "Outperform" Rating for Dyne Therapeutics (NASDAQ:DYN)marketbeat.com - March 26 at 10:46 AMDyne announces CEO transition, former Biogen exec tapped for top spotbizjournals.com - March 25 at 6:44 PMDyne Therapeutics Shares Drop 14% on CEO Joshua Brumm Departuremarketwatch.com - March 25 at 4:19 PMDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $28.24marketbeat.com - March 25 at 11:55 AMDyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO Transitionfinanznachrichten.de - March 25 at 9:25 AMDyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brummmarkets.businessinsider.com - March 25 at 9:25 AMDyne Therapeutics CEO Joshua Brumm to Exit For Investing Careermarketwatch.com - March 25 at 9:25 AMDyne Therapeutics Announces CEO Transitionglobenewswire.com - March 25 at 7:30 AMDyne Therapeutics (NASDAQ: DYN)fool.com - March 20 at 4:45 PMDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Updatemarketbeat.com - March 19 at 9:20 PMDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.4%marketbeat.com - March 18 at 11:56 AMDYN Apr 2024 30.000 putfinance.yahoo.com - March 18 at 12:21 AMWalleye Capital LLC Takes $2.51 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)marketbeat.com - March 17 at 4:20 AMDYN Apr 2024 22.500 callfinance.yahoo.com - March 16 at 6:15 PMDYN Apr 2024 30.000 callca.finance.yahoo.com - March 16 at 8:14 AMDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Vida Ventures Advisors LLCmarketbeat.com - March 14 at 6:40 PMNeuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surgemarkets.businessinsider.com - March 14 at 4:08 PMDyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells $58,904.40 in Stockinsidertrades.com - March 14 at 9:52 AMDyne Therapeutics to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 13 at 7:30 AMWildon Farwell Sells 1,585 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stockinsidertrades.com - March 13 at 7:20 AMSusanna Gatti High Sells 2,292 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stockmarketbeat.com - March 13 at 7:19 AMDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 2,672 Sharesinsidertrades.com - March 13 at 7:01 AMInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells 1,591 Shares of Stockinsidertrades.com - March 12 at 5:23 AMSusanna Gatti High Sells 1,591 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stockmarketbeat.com - March 11 at 10:33 PMDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Fmr LLCmarketbeat.com - March 9 at 4:21 AMChardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 8 at 1:25 PMHC Wainwright Comments on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)marketbeat.com - March 8 at 7:21 AM Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. DYN Media Mentions By Week DYN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.420.42▲Average Medical News Sentiment DYN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼143▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arvinas News Today Vera Therapeutics News Today Maravai LifeSciences News Today Deciphera Pharmaceuticals News Today Keros Therapeutics News Today Amphastar Pharmaceuticals News Today Rocket Pharmaceuticals News Today Indivior News Today TG Therapeutics News Today Avidity Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
